Corixa Corporation d.b.a. GlaxoSmithKline

Form 483FOIA Uncovered

Issued March 04, 2022

View FDA's Record for This Firm

Source: Third-party index, not matched to FDA. This record came from a third-party Form 483 index rather than from FDA directly, and we have not been able to match it to a document or an inspection FDA publishes. It stays out of the default view for that reason.

ObservationsNot available

Issue DateMarch 04, 2022

StatusNo Warning Letter

Related Inspections0

Establishment Details

Firm: Corixa Corporation d.b.a. GlaxoSmithKline
Location: N/A
FEI Number: N/A
Issue Date: March 04, 2022
Country: N/A

Inspection History

We hold no FDA inspection matched to this establishment.

Act on This Form 483

FDA Inspection ReadinessSee how your operations would hold up to the same scrutiny.CAPA & InvestigationsScore how you would investigate and close findings like these.Talk to a SpecialistWalk through these observations with a ComplianceQuest expert.

Corixa Corporation d.b.a. GlaxoSmithKline FDA Form 483, March 4, 2022